[go: up one dir, main page]

MX2013009529A - Tratamiento de enfermedad de crohn con fistulas. - Google Patents

Tratamiento de enfermedad de crohn con fistulas.

Info

Publication number
MX2013009529A
MX2013009529A MX2013009529A MX2013009529A MX2013009529A MX 2013009529 A MX2013009529 A MX 2013009529A MX 2013009529 A MX2013009529 A MX 2013009529A MX 2013009529 A MX2013009529 A MX 2013009529A MX 2013009529 A MX2013009529 A MX 2013009529A
Authority
MX
Mexico
Prior art keywords
disease
treatment
fistulizing crohn
crohn
fistulizing
Prior art date
Application number
MX2013009529A
Other languages
English (en)
Inventor
Ruehl Anne
Rogler Gerhard
Scharl Michael
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Publication of MX2013009529A publication Critical patent/MX2013009529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al campo de la enfermedad de Crohn, en particular se refiere al tratamiento de fístulas en la enfermedad de Crohn, usando anticuerpos anti-IL-13. El anticuerpo puede ser una lgG y, en particular, puede ser el anticuerpo anti-IL-13 019511G12.
MX2013009529A 2011-02-17 2012-02-15 Tratamiento de enfermedad de crohn con fistulas. MX2013009529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161443829P 2011-02-17 2011-02-17
PCT/IB2012/050699 WO2012110968A2 (en) 2011-02-17 2012-02-15 Treatment of fistulizing crohn's disease

Publications (1)

Publication Number Publication Date
MX2013009529A true MX2013009529A (es) 2016-09-21

Family

ID=45814532

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009529A MX2013009529A (es) 2011-02-17 2012-02-15 Tratamiento de enfermedad de crohn con fistulas.

Country Status (10)

Country Link
US (1) US20140050735A1 (es)
EP (1) EP2675477A2 (es)
JP (1) JP2014507436A (es)
KR (1) KR20140012093A (es)
CN (1) CN103458927A (es)
AU (1) AU2012219117A1 (es)
BR (1) BR112013020913A2 (es)
CA (1) CA2826543A1 (es)
MX (1) MX2013009529A (es)
WO (1) WO2012110968A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957530A2 (en) * 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
WO2015114593A2 (en) * 2014-02-03 2015-08-06 Novartis Ag Filters for infusion sets
WO2018183932A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2018182641A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Methods and ingestible devices for the regio-specific release of il-13 inhibitors at the site of gastrointestinal tract disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080044420A1 (en) * 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
EP1957530A2 (en) * 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses

Also Published As

Publication number Publication date
BR112013020913A2 (pt) 2016-10-11
CN103458927A (zh) 2013-12-18
WO2012110968A2 (en) 2012-08-23
EP2675477A2 (en) 2013-12-25
WO2012110968A3 (en) 2012-11-08
CA2826543A1 (en) 2012-08-23
AU2012219117A1 (en) 2013-08-22
KR20140012093A (ko) 2014-01-29
US20140050735A1 (en) 2014-02-20
JP2014507436A (ja) 2014-03-27

Similar Documents

Publication Publication Date Title
IL285522A (en) Human monoclonal antibodies that bind to 2-masp and suppress 2-masp-dependent complement activation, methods for their production and uses thereof
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
PL3604339T3 (pl) Terapeutyczne przeciwciała przeciwko białku ror-1 i sposoby ich zastosowania
SG178991A1 (en) Anti-gitr antibodies
MX2020011064A (es) Inmunoglobulinas heterodimericas.
EA201400579A1 (ru) Антитела к il-36r
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
PL2917229T3 (pl) Przeciwciała i ich fragmenty aktywowane przeciwko domenie alfa-3 białka HLA-G, sposoby i środki ich wytwarzania oraz ich zastosowania
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
SG11201402490XA (en) Methods of treatment using an antibody against interferon gamma
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2012006341A3 (en) Anti-ron antibodies
GB201109238D0 (en) Antibodies
MX343580B (es) Anticuerpos contra el g-csfr y sus usos.
EP2540744A4 (en) TOTALLY HUMAN MONOCLONAL ANTIBODY AGAINST VEGF, PREPARATION METHOD AND APPLICATION THEREOF
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
WO2012166659A3 (en) Anti-emr1 antibodies
TN2013000507A1 (en) Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer.
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof